135 related articles for article (PubMed ID: 38171332)
1. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation.
Si X; Shao M; Teng X; Huang Y; Meng Y; Wu L; Wei J; Liu L; Gu T; Song J; Jing R; Zhai X; Guo X; Kong D; Wang X; Cai B; Shen Y; Zhang Z; Wang D; Hu Y; Qian P; Xiao G; Huang H
Cell Metab; 2024 Jan; 36(1):176-192.e10. PubMed ID: 38171332
[TBL] [Abstract][Full Text] [Related]
2. Reductive carboxylation epigenetically instructs T cell differentiation.
Jaccard A; Wyss T; Maldonado-Pérez N; Rath JA; Bevilacqua A; Peng JJ; Lepez A; Von Gunten C; Franco F; Kao KC; Camviel N; Martín F; Ghesquière B; Migliorini D; Arber C; Romero P; Ho PC; Wenes M
Nature; 2023 Sep; 621(7980):849-856. PubMed ID: 37730993
[TBL] [Abstract][Full Text] [Related]
3. SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2.
Smolková K; Špačková J; Gotvaldová K; Dvořák A; Křenková A; Hubálek M; Holendová B; Vítek L; Ježek P
Sci Rep; 2020 May; 10(1):8677. PubMed ID: 32457458
[TBL] [Abstract][Full Text] [Related]
4. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
[TBL] [Abstract][Full Text] [Related]
5. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
6. P300/CBP-associated factor regulates transcription and function of isocitrate dehydrogenase 2 during muscle differentiation.
Savoia M; Cencioni C; Mori M; Atlante S; Zaccagnini G; Devanna P; Di Marcotullio L; Botta B; Martelli F; Zeiher AM; Pontecorvi A; Farsetti A; Spallotta F; Gaetano C
FASEB J; 2019 Mar; 33(3):4107-4123. PubMed ID: 30526058
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial NADP
Kong MJ; Han SJ; Kim JI; Park JW; Park KM
Cell Death Dis; 2018 May; 9(5):488. PubMed ID: 29695796
[TBL] [Abstract][Full Text] [Related]
8. Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation.
Corbet C; Pinto A; Martherus R; Santiago de Jesus JP; Polet F; Feron O
Cell Metab; 2016 Aug; 24(2):311-23. PubMed ID: 27508876
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors.
Hirabayashi K; Du H; Xu Y; Shou P; Zhou X; Fucá G; Landoni E; Sun C; Chen Y; Savoldo B; Dotti G
Nat Cancer; 2021 Sep; 2(9):904-918. PubMed ID: 34746799
[TBL] [Abstract][Full Text] [Related]
10. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
11. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
[TBL] [Abstract][Full Text] [Related]
12. Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice.
Li J; Zhou W; Li D; Huang Y; Yang X; Jiang L; Hu X; Yang J; Fu M; Zhang M; Wang F; Li J; Zhang Y; Yang Y; Yan F; Gao H; Wang W
Cancer Lett; 2023 Aug; 568():216287. PubMed ID: 37392990
[TBL] [Abstract][Full Text] [Related]
13. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
14. Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors.
Luo Q; Napoleon JV; Liu X; Zhang B; Zheng S; Low PS
Mol Cancer Res; 2022 May; 20(5):823-833. PubMed ID: 35135862
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells.
Rad S M AH; Halpin JC; Mollaei M; Smith Bell SWJ; Hirankarn N; McLellan AD
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799768
[TBL] [Abstract][Full Text] [Related]
16. Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart.
Karlstaedt A; Zhang X; Vitrac H; Harmancey R; Vasquez H; Wang JH; Goodell MA; Taegtmeyer H
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10436-41. PubMed ID: 27582470
[TBL] [Abstract][Full Text] [Related]
17. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
18. Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
Sun S; Huang C; Lu M; Xu H; Yuan Y; Zhao W; Hu X; Wang B; Zhang W; Gao X; Zheng J; Su L; Zhang Q
Cancer Immunol Res; 2023 Apr; 11(4):515-529. PubMed ID: 36689620
[TBL] [Abstract][Full Text] [Related]
19. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status.
Yu W; Dittenhafer-Reed KE; Denu JM
J Biol Chem; 2012 Apr; 287(17):14078-86. PubMed ID: 22416140
[TBL] [Abstract][Full Text] [Related]
20. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
Shen L; Xiao Y; Tian J; Lu Z
Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
